Tsinghua University Holdings (TUS) of Beijing will invest $276 million to build a new biohub in the UK’s Cambridge Science Park (see story). The biohub will be a joint venture between TUS and Trinity College, Cambridge, the owner of the park. The money will build five new buildings, comprising 350,000 square feet. This includes a state-of-the-art biohub, which will provide labs and offices for early stage companies working on a wide range of healthcare technologies, including non-invasive diagnostics, new drugs, novel surgical techniques and new home-monitoring technologies.  

Jing Medicine Technology (Shanghai) will collaborate with ShanghaiTech University in a $100 million partnership to discover and develop novel small molecule cancer drugs (see story). Jing Medicine will own global development and commercialization rights to the candidates, while ShanghaiTech University will receive upfront and milestone payments plus royalties. Initially, the partnership will focus on novel IP-protected compounds from a Ligand-directed Protein Degradation Platform, developed by Professor Biao Jiang.  

Beijing InnoCare Pharma raised $55 million in a funding round led by Vivo Capital and joined by CCB Capital (see story). InnoCare is developing a portfolio of novel drugs for cancer and autoimmune diseases, using a combination of in-licensing and internal research. The company hopes its candidates, which target both China and global markets, will prove to be either first-in-class or best-in-class. InnoCare expects to release “landmark” clinical trial results this year.  

China’s GeneScience Pharma was a new investor in Rani Therapeutics’ latest $53 million fundraising (see story). Rani, a Bay Area company, is developing pills that replace injectible delivery mechanisms to treat chronic diseases such as diabetes and arthritis. GeneScience hinted at a future tie-up between the two companies, though no agreement was announced. Rani will use the capital to build a manufacturing facility to supply products for clinical trials.